From Pathway to Network Disruption: The Neurobiology of Schizophrenia

This article examines schizophrenia as a disorder involving interactions among neurotransmitter pathways, describing how dopaminergic, serotonergic, glutamatergic, GABAergic, and cholinergic dysfunctions may converge at the synaptic, circuit, and network levels. The article connects these pathway-level disruptions to heterogeneity across clinical symptom domains, supporting a broader disease-focused model of schizophrenia neurobiology.

Introduction

Schizophrenia is a complex, heterogeneous psychiatric disorder whose pathophysiology cannot be attributed to dysfunction within any single neurotransmitter system.^1,2 Pharmacologic, neuroimaging, electrophysiologic, and postmortem evidence suggest a multi-pathway model in which dopaminergic, serotonergic, glutamatergic, GABAergic, and cholinergic systems interact within and across neural circuits which may lead to the characteristic symptom domains observed in people with schizophrenia.^1,2,3 This article builds on foundational pathway concepts to analyze how dysfunction across these interacting systems may contribute to the neurobiology of schizophrenia and how pathway-level disruptions can lead to network-level changes observable in neuroimaging studies.

Pathway-Level Mechanisms in Schizophrenia

Understanding the neurobiology of schizophrenia requires examining each implicated neurotransmitter system with mechanistic specificity, while recognizing that these systems are not independent of one another.¹ Abnormalities in one pathway may alter the function of others, and the clinical expression of schizophrenia reflects the cumulative effects of these interactions.^1,2,3

Dopaminergic Dysregulation

Elevated striatal dopamine release is one of the most replicated findings in schizophrenia research, both preclinical and clinical.^1,2,3 However, dopaminergic dysregulation is not uniform across brain regions in schizophrenia: the mesolimbic pathway, projecting from the brainstem to the striatum, shows hyperactivity thought to be associated with positive symptoms, such as hallucinations and delusions.^1,2 On the other hand, the mesocortical pathway, projecting from the brainstem to the prefrontal cortex, exhibits relative hypoactivity thought to be associated with negative and cognitive symptoms.^2,3 

Importantly, striatal dopamine hyperactivity in schizophrenia is understood to reflect upstream disinhibition rather than intrinsic dopaminergic dysfunction.^2,4 Reduced GABAergic control over midbrain dopaminergic neurons and altered glutamatergic drive from the prefrontal cortex both are thought to contribute to the excess dopamine release observed in mesolimbic circuits, illustrating how dopaminergic dysregulation is embedded within the broader multi-pathway context.^1,2,4

Serotonergic Modulation

Serotonin, acting primarily through 5-HT2A receptors expressed on cortical glutamatergic neurons, exerts excitatory effects on glutamate release.¹ Hyperactivation of 5-HT2A receptors is hypothesized to increase downstream glutamate signaling in prefrontal-to-subcortical circuits, leading to secondary increases in mesolimbic dopamine output.¹ 5-HT2A agonists support the hypothesis of serotonergic contribution to psychosis.¹

Glutamatergic Dysfunction and NMDA Receptor Hypofunction

The glutamate hypothesis of schizophrenia centers on the hypofunction of N-methyl-D-aspartate (NMDA) receptors, particularly those expressed on cortical GABA interneurons.⁵ NMDA receptor antagonists have been shown to reproduce the symptoms of schizophrenia in healthy individuals.^1,5 It was this observation that initially established NMDA hypofunction as a convergence point across symptom domains.

The cellular mechanism linking NMDA hypofunction to clinical symptoms involves preferential loss of excitatory drive onto fast-spiking GABA interneurons.^4,5 These interneurons, highly sensitive to NMDA receptor blockade due to their rapid firing rates, lose inhibitory tone when NMDA function is impaired.^4,5 The resulting disinhibition of excitatory neurons is thought to produce cortical overactivity and may result in disrupted signaling required for coordinated cognitive processing.^4,5

Glutamatergic dysfunction also propagates downstream to subcortical circuits.² Increased glutamatergic output to the striatum and midbrain is thought to increase excitation of dopaminergic neurons, contributing to increased dopamine release in the striatum.^2,4 This glutamate-dopamine interaction suggests a mechanistic bridge between two hypothesized pathways in schizophrenia and may explain why dopaminergic symptoms may arise from upstream cortical glutamatergic deficits.^1,2

GABAergic Inhibitory Circuit Disruption

Inhibitory GABA interneurons serve as critical regulators of excitation–inhibition (E/I) balance throughout cortical and subcortical circuits.⁶ Postmortem analyses have identified reduced expression of glutamic acid decarboxylase 67 (GAD67)—the primary GABA-synthesizing enzyme—in the prefrontal cortex of people with schizophrenia.^4,6,7

GABA interneurons coordinate the rapid neuronal firing required for working memory maintenance and sensory processing.^5,6 Their loss of function in schizophrenia could result in cognitive function and negative symptom domains of schizophrenia.^4,6

In the midbrain, GABA interneurons may exert constant inhibitory control over mesolimbic dopaminergic neurons. Postmortem and preclinical evidence indicate that reduced GABA inhibitory tone in the midbrain promotes dopaminergic disinhibition, contributing to the excess striatal dopamine implicated in the positive symptoms of schizophrenia.^4,7

Cholinergic Modulation

The cholinergic system occupies an integrative neuromodulatory position across circuits implicated in schizophrenia.^8,9 Muscarinic and nicotinic cholinergic receptors are widely expressed in the cortex, hippocampus, and striatum—regions that demonstrate structural and functional abnormalities in schizophrenia.^8-10 Postmortem and neuroimaging studies have reported reductions in M1 and M4 muscarinic and a7 nicotinic receptor availability in people with schizophrenia.^9,10

In cortical and hippocampal circuits, muscarinic receptor activation modulates glutamatergic signaling and network excitability.^8,9 M1 receptor activation on GABA interneurons in the prefrontal cortex is thought to facilitate inhibitory GABA release, reducing excitatory neuron output and helping restore E/I balance, directly countering GABA interneuron dysfunction.⁹ α7 nicotinic receptors are similarly expressed on GABAergic interneurons, where their activation is thought to modulate glutamatergic input and may contribute to E/I regulation in the same circuits.⁹ The M1-mediated increase in cortical inhibitory tone also reduces glutamatergic drive onto mesolimbic dopaminergic neurons, thereby decreasing dopamine release in the striatum.⁹ M4 muscarinic receptor activation provides a complementary presynaptic mechanism: by suppressing acetylcholine release from inputs to the mesolimbic pathway, M4 agonism further reduces striatal dopamine release.^8,9 Together, M1 and M4 receptor agonism represent a route that may help address both increased striatal dopamine signaling and E/I imbalance.^8,9

Clinical Implications of the Multi-Pathway Model

A defining feature of the multi-pathway model of schizophrenia is that these neurotransmitter systems do not operate independently—they form a functionally integrated network in which disruption of one pathway propagates across others.^1,2 Positive symptoms are predominantly thought to reflect excess dopamine release in the striatum, itself driven by upstream NMDA hypofunction, GABA disinhibition, serotonin-mediated excitation, and altered muscarinic signaling.^1,9 Negative symptoms are thought to emerge from reduced dopamine signaling in the cortex, impaired prefrontal glutamatergic engagement, and loss of cholinergic and GABAergic modulation.^2,5,6,8,10 Cognitive symptoms may reflect disrupted E/I balance in prefrontal cortical circuits thought to be driven by NMDA hypofunction, GABA interneuron dysfunction, and impaired cholinergic and serotonergic modulation.^1,5,6,9

Understanding the multi-pathway model may help elucidate the disease heterogeneity of schizophrenia, such as the variation in symptom profiles and illness trajectory across individuals and may provide a better understanding of overall clinical assessment.² A multi-pathway understanding may ultimately support individualized approaches to clinical assessment.²

Conclusion

To reiterate, schizophrenia emerges from coordinated dysfunction across dopaminergic, serotonergic, glutamatergic, GABAergic, and cholinergic neurotransmitter systems that interact at the synaptic, circuit, and network levels.^1-3 These pathways are interconnected: NMDA hypofunction drives GABA interneuron failure, which disinhibits mesolimbic dopamine release and disrupts cortical signaling; serotonergic hyperactivity amplifies glutamatergic and dopaminergic dysregulation; and cholinergic deficits impair the neuronal infrastructure that normally coordinates excitability across cortical and subcortical circuits.^1,2,4,8,9

These interacting pathway-level disturbances may account for the biologic and clinical heterogeneity that defines schizophrenia—the divergent clinical presentations, disease trajectories, and management.^2,3

References

1. Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187-191. doi:10.1017/S1092852918001013
2. Howes OD, Dawkins E, Lobo MC, Kaar SJ, Beck K. New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction. Biol Psychiatry. 2024;96(8):638-650. doi:10.1016/j.biopsych.2024.05.014
3. Peng A, Chai J, Wu H, Bai B, Yang H, He W, et al. New therapeutic targets and drugs for schizophrenia beyond dopamine D2 receptor antagonists. Neuropsychiatr Dis Treat. 2024;20:607-620.
4. Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010;12(3):359-382.  
5. Snyder MA, Gao WJ. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci. 2013;7:31.
6. Liu Y, Ouyang P, Zheng Y, Mi L, Zhao J, Ning Y, et al. A selective review of the excitatory-inhibitory imbalance in schizophrenia: underlying biology, genetics, microcircuits, and symptoms. Front Cell Dev Biol. 2021;9:664535.
7. Purves-Tyson TD, Brown AM, Weissleder C, Rothmond DA, Weickert CS. The inhibitory circuitry of the midbrain and its disruption in schizophrenia. Mol Brain. 2021;14:96.  
8. Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021;405:113201.  
9. Meyer JM, Kramer K, Vuocolo S, Kaul I, Miller AC. From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. Int J Neuropsychopharmacol. 2025;28(4):pyaf015. doi:10.1093/ijnp/pyaf015
10. Saint-Georges Z, MacDonald J, Al-Khalili R, Hamati R, Solmi M, Keshaven MS, et al. Cholinergic system in schizophrenia: a systematic review and meta-analysis. Mol Psychiatry. 2025;30(7):3301-3315.

© 2026 Bristol-Myers Squibb Company
NS-US-2600095 08/26